HANK + ETBX-011 + GI-4000

A combination investigational immunotherapy regimen consisting of HANK, ETBX-011, and GI-4000, developed for the treatment of cancers expressing specific tumor-associated antigens. - **ETBX-011** is an adenoviral vector-based cancer vaccine encoding carcinoembryonic antigen (CEA), designed to activate immune responses—both humoral and T-cell responses—against CEA-positive cancer cells. It has been studied primarily in colorectal and pancreatic cancer, and is administered subcutaneously. It was developed by Etubics (now part of ImmunityBio) and has been tested both as a monotherapy and in combination with other immunotherapies[1][3][5][7]. - **GI-4000** is a recombinant yeast-based vaccine expressing one of several mutated RAS proteins (KRAS, HRAS, or NRAS), targeting cancer cells with these common oncogenic drivers, mainly in pancreatic and colorectal cancer. It elicits a T-cell-mediated response against RAS-mutant cells and is also administered subcutaneously. Developed by GlobeImmune, GI-4000 has shown immunogenicity in clinical trials[2][4][6][8]. - **HANK** could not be definitively identified in the scientific or clinical literature as an independent investigational or approved drug; no reliable information available on its mechanism or developer in the context of this combination. This combination represents an investigational immunotherapeutic strategy primarily directed at cancers expressing CEA or mutated Ras proteins, notably in colorectal and pancreatic cancers.

Other names

HANK + ETBX-011 + GI-4000